A semi-automated production line will be set up in the future facility, which can be expanded to include additional active ingredients if required. The proximity to medical centres and transport routes meets important logistical requirements, a decisive advantage when radioactive preparations need to be delivered to patients quickly. Novartis is currently the only company in Germany with two approved RLT products and is pursuing ambitious plans: new isotopes, ligands and combination therapies are to extend the areas of application beyond prostate cancer to include cancers such as breast, colon, lung and pancreatic cancer. For the region, the new building not only means a considerable investment, according to press reports around 35 to 40 million euros, but also new jobs and a strengthening of Halle as a centre of science. With this decision, Novartis is sending a strong signal: in future, radioligand therapy will not only be developed innovatively in Germany, but also produced locally and made available quickly. This will bring industry, research and patient care closer together.
Press release from "Novartis Pharma GmbH" dated 10 November 2025